HKSE · 1801.HK
Innovent Biologics, Inc.
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
Loading market information…
HKSE · 6990.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.17% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s next earnings report is currently expected on Mar 29, 2027, with estimated earnings per share of HK$0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| HK$1.49B+61.62% vs estimate |
| Q4 2023 | Mar 25, 2024 | -HK$2.72-81.0% vs estimate | HK$522.62M-42.24% vs estimate |
|---|
| Q2 2023 | Aug 28, 2023 | -HK$0.18+95.33% vs estimate | HK$1.13B+162.85% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$81.95+HK$0.35 (+0.43%)
Innovent Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.28% below the high.
HK$83.45-HK$0.05 (-0.06%)
Akeso, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.51% below the high.
HK$17.55-HK$0.13 (-0.74%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
HK$21.12-HK$0.04 (-0.19%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 17.44% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$23.36-HK$1.60 (-6.41%)
GenFleet Therapeutics (Shanghai) Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.84% below the high.
HK$4.95+HK$0.21 (+4.44%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
HK$2.84+HK$0.02 (+0.53%)
Antengene Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 54.78% below the high.
